ArticleJugan geon-gang gwa jilbyeong2024
[National Surveillance and Response to Possible and Suspected Middle East Respiratory Syndrome Cases in the Republic of Korea, 2022].
Article in Jugan geon-gang gwa jilbyeong, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surveillance System for Infectious Disease Prevention and Management: Direction of Korea's Infectious Disease Surveillance System.Journal of Korean medical science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Middle East Respiratory Syndrome (MERS) is an acute respiratory infection transmitted mainly through camels and individuals infected with the MERS-CoV. It was first reported in Saudi Arabia in 2012 and is predominantly prevalent in the Middle East. By 2022, there were 341 possible cases of MERS in the Republic of Korea. The winter months of January and February contributed to 30.2% (103 cases) of all reports in 2022, followed by a decrease; however, an increase was observed during the second half of the year. This is presumed to be attributed to the simultaneous response policy to coronavirus disease 2019 (COVID-19) and MERS implemented in December 2021, the international easing of COVID-19 prevention measures, an increase in travelers from the Middle East, and seasonal factors. Among the 341 possible MERS cases reported in 2022, 122 suspected MERS cases classified as underwent MERS testing with no confirmed cases. Moreover, to efficiently prevent the influx of MERS, along with COVID-19 prevention measures during the quarantine stage, a simultaneous response policy to COVID-19 and MERS was implemented in December 2021. Suspected MERS cases were transferred to quarantine facilities within the quarantine station for simultaneous testing for COVID-19 and MERS, replacing the previous practice of conducting tests after transfer to hospitals. This convenience appears to have led to the proactive reporting and surveillance of possible MERS symptoms at the quarantine stage. Therefore, we propose further analyses on the convenience of conducting MERS tests at quarantine facilities and their impact on MERS surveillance. This information can be actively utilized in the development of new MERS surveillance systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.